Improving Cardiovascular Outcomes for Patients with Heart Failure in Sub-Saharan Africa: Conference Proceedings of the 2022 Nigerian Cardiovascular Symposium

Overview

Journal Cardiovasc J Afr

Specialty Cardiology & Vascular Diseases

Date 2023 May 5

PMID 37145711

Authors

Onyedika J Ilonze

Albert Hicks

Bayo Atanda

Mahmoud H Abdou

Chioma Onyekwelu

Ebere Chukwu

Kamilu M Karaye

Ibraheem Katibi

Okechukwu S Ogah

Obi Emerole

Jane N Ajuluchukwu

Mahmoud U Sani

Christopher C Asuzu

Modele O Ogunniyi

Affiliations

Soon will be listed here.

Abstract

The Nigerian Cardiovascular Symposium is an annual conference held in partnership with cardiologists in Nigeria and the diaspora to provide updates in cardiovascular medicine and cardiothoracic surgery with the aim of optimising cardiovascular care for the Nigerian population. This virtual conference (due to the COVID-19 pandemic) has created an opportunity for effective capacity building of the Nigerian cardiology workforce. The objective of the conference was for experts to provide updates on current trends, clinical trials and innovations in heart failure, selected cardiomyopathies such as hypertrophic cardiomyopathy and cardiac amyloidosis, pulmonary hypertension, cardiogenic shock, left ventricular assist devices and heart transplantation. Furthermore, the conference aimed to equip the Nigerian cardiovascular workforce with skills and knowledge to optimise the delivery of effective cardiovascular care, with the hope of curbing 'medical tourism' and the current 'brain drain' in Nigeria. Challenges to optimal cardiovascular care in Nigeria include workforce shortage, limited capacity of intensive care units, and availability of medications. This partnership represents a key first step in addressing these challenges. Future action items include enhanced collaboration between cardiologists in Nigeria and the diaspora, advancing participation and enrollment of African patients in global heart failure clinical trials, and the urgent need to develop heart failure clinical practice guidelines for Nigerian patients.

Citing Articles

Uneven burden of cardiac amyloidosis in people of African descent - global imbalance in resources and access.

Madu E, Mezue K BMC Glob Public Health. 2024; 1(1):15.

PMID: 39681929 PMC: 11622854. DOI: 10.1186/s44263-023-00016-3.

References

Teuteberg J, Slaughter M, Rogers J, McGee E, Pagani F, Gordon R . The HVAD Left Ventricular Assist Device: Risk Factors for Neurological Events and Risk Mitigation Strategies. JACC Heart Fail. 2015; 3(10):818-28. DOI: 10.1016/j.jchf.2015.05.011. View

Pettit S, Petrie M, Connelly D, Japp A, Payne J, Haj-Yahia S . Use of implantable cardioverter defibrillators in patients with left ventricular assist devices. Eur J Heart Fail. 2012; 14(7):696-702. DOI: 10.1093/eurjhf/hfs062. View

Slaughter M, Rogers J, Milano C, Russell S, Conte J, Feldman D . Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009; 361(23):2241-51. DOI: 10.1056/NEJMoa0909938. View

van den Berg M, Mulder B, Klaassen S, Maass A, Van Veldhuisen D, van der Meer P . Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. Eur Heart J. 2019; 40(16):1287-1293. PMC: 6553504. DOI: 10.1093/eurheartj/ehz057. View

Sliwa K, Mayosi B . Recent advances in the epidemiology, pathogenesis and prognosis of acute heart failure and cardiomyopathy in Africa. Heart. 2013; 99(18):1317-22. DOI: 10.1136/heartjnl-2013-303592. View

Benson M, Waddington-Cruz M, Berk J, Polydefkis M, Dyck P, Wang A . Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018; 379(1):22-31. DOI: 10.1056/NEJMoa1716793. View

Castano A, Haq M, Narotsky D, Goldsmith J, Weinberg R, Morgenstern R . Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiol. 2016; 1(8):880-889. DOI: 10.1001/jamacardio.2016.2839. View

Watson C, Dark J . Organ transplantation: historical perspective and current practice. Br J Anaesth. 2011; 108 Suppl 1:i29-42. DOI: 10.1093/bja/aer384. View

Gertz M, Adams D, Ando Y, Beirao J, Bokhari S, Coelho T . Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract. 2020; 21(1):198. PMC: 7513485. DOI: 10.1186/s12875-020-01252-4. View

10.

Castellano J, Pocock S, Bhatt D, Quesada A, Owen R, Fernandez-Ortiz A . Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022; 387(11):967-977. DOI: 10.1056/NEJMoa2208275. View

11.

Heidenreich P, Bozkurt B, Aguilar D, Allen L, Byun J, Colvin M . 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18):e895-e1032. DOI: 10.1161/CIR.0000000000001063. View

12.

Pitt B, Pfeffer M, Assmann S, Boineau R, Anand I, Claggett B . Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370(15):1383-92. DOI: 10.1056/NEJMoa1313731. View

13.

Park S, Milano C, Tatooles A, Rogers J, Adamson R, Steidley D . Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012; 5(2):241-8. DOI: 10.1161/CIRCHEARTFAILURE.111.963991. View

14.

Moon S, Mariat S, Kamae I, Bak Pedersen H . Defining the concept of fair pricing for medicines. BMJ. 2020; 368:l4726. DOI: 10.1136/bmj.l4726. View

15.

Marian A, Braunwald E . Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017; 121(7):749-770. PMC: 5654557. DOI: 10.1161/CIRCRESAHA.117.311059. View

16.

Agbor-Enoh S, Shah P, Tunc I, Hsu S, Russell S, Feller E . Cell-Free DNA to Detect Heart Allograft Acute Rejection. Circulation. 2021; 143(12):1184-1197. PMC: 8221834. DOI: 10.1161/CIRCULATIONAHA.120.049098. View

17.

Budhram S, Krishundutt P . A three-year audit of pregnancy outcomes in women with pulmonary hypertension admitted to the high-risk obstetric unit at Inkosi Albert Luthuli Central Hospital, KwaZulu-Natal, South Africa. Cardiovasc J Afr. 2022; 34(5):285-290. PMC: 11047714. DOI: 10.5830/CVJA-2022-061. View

18.

King P, Kates A . Management of Cardiac Symptoms in Amyloidosis. Am J Med. 2022; 135 Suppl 1:S9-S12. DOI: 10.1016/j.amjmed.2022.02.005. View

19.

Givertz M, Defilippis E, Colvin M, Darling C, Elliott T, Hamad E . HFSA/SAEM/ISHLT clinical expert consensus document on the emergency management of patients with ventricular assist devices. J Heart Lung Transplant. 2019; 38(7):677-698. DOI: 10.1016/j.healun.2019.05.004. View

20.

Mehra M, Uriel N, Naka Y, Cleveland Jr J, Yuzefpolskaya M, Salerno C . A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. N Engl J Med. 2019; 380(17):1618-1627. DOI: 10.1056/NEJMoa1900486. View